OCTOBER 6, 2017

This week's sponsor:

TOPIndustry NEWS

Selected by DCAT Editorial Director Patricia Van Arnum

1. Gilead Completes $11.9-Billion Acquisition of Kite Pharma
Gilead Sciences has completed its $11.9-billion acquisition of Kite Pharma, a company engaged in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. Read More

2. Amgen in Immuno-Oncology Pact Worth up to $1.4 Billion
Amgen and CytomX Therapeutics, a biopharmaceutical company, have partnered in a deal worth up to $1.4 billion, to co-develop bispecific antibody constructs for immuno-oncology. Read More

3. Merck KGaA To Invest $41 Million for New Injectables Mfg Line
Merck KGaA is investing EUR 35 million ($41 million) in a new production line for aseptic filling under isolators at its site in Bari, Italy. The new line is expected to be fully operational in 2022. Read More

4. Mylan Launches Generic of Novartis' Top-Selling Drug Gleevec
Mylan has launched imatinib mesylate tablets, a generic version of Novartis's top-selling drug, Gleevec (imatinib mesylate), an anticancer drug, which had 2016 global sales of $3.3 billion. Read More

5. FDA OKs Mylan's Generic of Teva's Top-Selling MS Drug Copaxone
The FDA has approved two dosings of Mylan's glatiramer acetate injection, a generic of Teva's top-selling drug, Copaxone (glatiramer acetate), for treating multiple sclerosis. Read More

6. Lonza Acquires US Clinical Biomfg Facility
Lonza has agreed to acquire a clinical-stage mammalian manufacturing site in the US from Shire and is nearing completion of a cell and gene therapy manufacturing facility near Houston, Texas. Read More

7. FDA Issues Final Guidance on Emerging Drug Manufacturing Technologies
The FDA has issued final guidance to give recommendations to pharmaceutical companies interested in participating in a program involving the submission of chemistry, manufacturing, and controls information containing emerging technology to the FDA. Read More

8. FDA Issues Draft Guidance for Complex Generic Drugs
In a move to facilitate the generic-drug review process and drug competition, the FDA has issued two draft guidance documents relating to the generic-drug review process for complex generics and outlined future policy considerations for complex generic drugs. Read More

9. FDA Issues Draft Guidance for Generic-Drug Review Process
The FDA has issued two draft guidance documents related to improving the generic-drug review process when submitting abbreviated new drug applications. Read More

10. GE Healthcare Opens 3D-Printing Mfg Center for Pharma
GE Healthcare has opened its first 3D printing lab in Uppsala, Sweden. GE is testing the performance of a 3D-printed chromatography column with Amgen for biopharmaceutical purification. Read More

*Top Industry News is published and distributed by the **Drug, Chemical & Associated Technologies Association** (DCAT). The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum. For more information, visit **www.dcat.org**.*

STAY CONNECTED